Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Advanced Primary Liver Cancer
NCT00582400Phase 2Terminated
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Sep 2004
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoints: Number of Participants With Treatment Related Toxicity at 6 years and Number of Patients With Response to Treatment (RECIST Criteria) at 6 years. Started Sep 2004; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT00582400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582400.